Journal
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
Volume 38, Issue 4, Pages S495-S501Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amepre.2009.12.017
Keywords
-
Funding
- Eisai
- GlaxoSmithKline
Ask authors/readers for more resources
Venous thromboembolism (VTE), defined as deep vein thrombosis, pulmonary embolism, or both, affects an estimated 300,000-600,000 individuals in the U.S. each year, causing considerable morbidity and mortality. It is a disorder that can occur in all races and ethmaties, all age groups, and both genders. With many of the known risk factors-advanced age, immobility, surgery, obesity-Increasing in society, VTE is an important and growing public health problem. Recently, a marked increase has occurred in federal and national efforts to raise awareness and acknowledge the need for VTE prevention. Yet, many basic public health functions-surveillance, research, and awareness are still needed. Learning and understanding more about the burden and causes of VTE, and raising awareness among the public and healthcare providers through a comprehensive public health approach, has enormous potential to prevent and reduce death and morbidity from deep vein thrombosis and pulmonary embolism throughout the U.S (Am J Prey Med 2010,38(4S).S495-S501) Published by Elsevier Inc on behalf of American Journal of Preventive Medicine
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available